Stablix Appoints Eddine Saiah Chief Scientific Officer and Expands Leadership Team

NEW YORK–(BUSINESS WIRE)–Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer. Dr. Saiah is an experienced drug hunter and seasoned leader with over 25 years of experience heading drug discovery, preclinical and early development in … [Read more…]

Normalizing Utilization and Pivot to Value-Based Care Delivery Models Present Opportunities for Employer-Sponsored Health Plans, J.D. Power Finds

Call Center Customer Support and Digital Tools Emerge as Key Areas in Need of Improvement TROY, Mich.–(BUSINESS WIRE)–With pandemic-driven volatility in healthcare starting to subside, health spending and utilization are projected to normalize1 during the next two years. According to the J.D. Power 2022 U.S. Commercial Member Health Plan Study,SM released today, that return to … [Read more…]

Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox

The Roblox vision for bringing people together through shared experiences, plus the Akili commitment to a new era of cognitive medicine, make the companies ideal partners to deliver a reimagined patient experience BOSTON & SANTA MONICA, Calif.–(BUSINESS WIRE)–Akili Interactive (“Akili”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, and … [Read more…]

Alchemab Appoints Young T. Kwon as Chief Executive Officer

WALTHAM, Mass. & CAMBRIDGE, England–(BUSINESS WIRE)–Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, announced that Young T. Kwon, PhD, Alchemab’s Chief Financial and Operating Officer, has succeeded Douglas A. Treco, PhD as Chief Executive Officer and member of the Board, who resigned … [Read more…]

Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2022. Corporate and Clinical Development Highlights Include: Fortified Balance Sheet – On March 31, 2022, Can-Fite … [Read more…]

VirtaMed and Medical Microinstruments Partner to Advance the Skills of Surgeons Performing Complex Robotic Microsurgeries

VirtaMed’s VR simulations provide advanced training for surgeons using MMI’s Symani® Robotic System and introduce new product testing capabilities ZURICH–(BUSINESS WIRE)–VirtaMed, a world leader in medical simulation training, and Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, have announced a partnership where surgeons using MMI’s Symani® Surgical … [Read more…]

908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference

BOSTON–(BUSINESS WIRE)–908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will be participating in the upcoming William Blair 42nd Annual Growth Stock Conference. 908 Devices’ management is scheduled to present on Thursday, June 9th, at 8:00 a.m. Central Time / 9:00 … [Read more…]

Flagship Pioneering Unveils ProFound™ Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New Medicines

The Company’s ProFoundry™ Platform has to date identified tens of thousands of previously undiscovered proteins that represent a vastly expanded number of therapeutic targets Flagship commits $75 million to enable the continued expansion of the ProFoundry™ Platform to support target discovery efforts and building of a robust R&D pipeline CAMBRIDGE, Mass.–(BUSINESS WIRE)–Flagship Pioneering, the bioplatform … [Read more…]

Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

WILMINGTON, Del.–(BUSINESS WIRE)–$INCY #EHA2022–Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and in Vienna). “We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with … [Read more…]